Literature DB >> 16259582

Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.

Lawrence M DuBuske1.   

Abstract

Desloratadine is a once-daily, non-sedating, non-impairing, selective histamine H1-receptor antagonist. It relieves the symptoms of seasonal allergic rhinitis (including nasal obstruction and congestion, and morning symptoms), perennial allergic rhinitis and chronic idiopathic urticaria by blocking multiple critical steps in the systemic allergic cascade and downregulating key allergy-induced inflammatory mediators. It also relieves asthma symptoms and decreases rescue medication use in patients with seasonal allergic rhinitis and comorbid asthma. Numerous clinical studies have demonstrated that desloratadine is safe, well tolerated and free of serious cardiac effects. Pharmacokinetic studies have demonstrated a low propensity for drug-drug or drug-food interactions. This review outlines the mechanism of action, efficacy and safety of desloratadine for the treatment of allergic inflammatory disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259582     DOI: 10.1517/14656566.6.14.2511

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  2 in total

1.  A Novel Desloratadine-Benzoic Acid Co-Amorphous Solid: Preparation, Characterization, and Stability Evaluation.

Authors:  Ahmad Ainurofiq; Rachmat Mauludin; Diky Mudhakir; Sundani Nurono Soewandhi
Journal:  Pharmaceutics       Date:  2018-07-06       Impact factor: 6.321

2.  Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence.

Authors:  G Walter Canonica; Michael Blaiss
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.